🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Mexico / NCT06468553
Recruiting Not applicable

Multidisciplinary Care for Lifestyle Change for Metabolic Control and Quality of Life in Prediabetes (PreCPro)

NCT06468553 · tracked via the Priya Life Science Mexico tracker
Sponsor
Clinica Especializada en el Manejo de la Diabetes en la Ciudad de Mexico
Phase
Not applicable
Started
2023-03-01
Last updated
2024-06-21

Condition(s) studied

PreDiabetes

Investigational drug(s) / intervention(s)

Prediabetes Care Program

Prediabetes Care Program: Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months

Study summary

Prediabetes is part of the natural history of type 2 diabetes mellitus, which is one of the main causes of morbidity and mortality in Mexico. It is known that overweight and obesity are the main risk factors for producing insulin resistance and this in turn leads to prediabetes-diabetes mellitus 2, acting alone or together, excess adipose tissue, mainly visceral, and Prediabetes increase cardiovascular risk before hyperglycemia occurs in the diagnostic criteria for diabetes. Effective strategies have been developed focused on changing lifestyle habits (changes in dietary patterns and increased physical activity) to promote weight loss in populations with and without glucose alterations present, but with limitations in the scope for the size of the affected population. There is a small number of studies developed for this purpose, focused on a multidisciplinary intervention in low- and middle-income countries. The prediabetes care program (PreCPro) is a care initiative developed by the primary care public health services of the Government of Mexico City (CDMX) to promote weight reduction and reduction of hyperglycemia through a intervention composed of an interdisciplinary care team, centered on the patient with a focus on promoting change in people's behavior to adopt healthy eating and physical activity habits. The target population of the prediabetes care program (PreCPro) is made up of patients with prediabetes, without advanced diseases, who receive regular care in public primary care services in Mexico City.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Having diagnosis of prediabetes * Acceptance for participation in the program by signing informed consent sheet Exclusion Criteria: * Any type of diabetes * Advanced diseases such as ischemic heart disease, heart failure, KDOQI renal failure ≥1, cerebral vascular disease with functional sequelae or those who have comorbidities that limit their life expectancy such as malignant tumors in advanced stages * Dependence of illicit drugs * Conditions that require short-term surgical treatment. * Pregnancy * Advanced cognitive deficit or serious psychiatric disorders that hinder treatment adherence * Use of medications whose use is associated with alterations in blood glucose levels or weight gain or loss, e.g. e.g. metformin, Glucagon-like peptide-1 receptor agonists, orlistat or corticosteroids * Actively taking any supplements dietary or under naturopathic, homeopathic or alternative therapies * Have any type of bariatric surgery procedure or weight loss device * Current participation in another lifestyle, behavior change, or weight loss or gain program or research study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinica Especializada en el Manejo de la Diabetes Mexico City Iztapalapa Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06468553 on ClinicalTrials.gov ↗ ← All trials in Mexico